Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ future pipeline to focus more on complex generics—drugs that have ...

Global pharmaceutical company Pfizer (NYSE:PFE) in Q1 CY2025, with sales falling 7.8% year on year to $13.72 billion. The ...

Drugmaker Viatris beat Wall Street estimates for first-quarter profit and revenue on Thursday, helped by sales of its branded drugs in China.

Dual chamber prefilled syringes market is estimated to be valued at $ 184.7 Mn in 2025, and is expected to reach $ 306.6 Mn by 2032, exhibiting a CAGR of 7.5%. BURLINGAME, CA, UNI ...

SaaS revenue grows 16% (constant currency1 17%), adjusted EBITDA1 margin of 25% Annual recurring revenue2 grows 14% (constant currency1 14%) FY 2025 guidance reiterated after solid first quarter ...

SAN CLEMENTE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial ...

Amid the ongoing uncertainty about tariffs, muted earnings season, and recession concerns, the stock market has remained ...

ATB Capital Markets analyst Martin Toner has to maintained his “Outperform” rating and $210.00 price target on KXS.

Royalty Receipts was $788 million in the first quarter of 2025, an increase of 12% compared to $705 million in the first quarter of 2024. The increase was primarily driven by strong growth from the ...

Investors are closely monitoring the performance of Indian pharma companies in the March 2025 quarter and their ability to ...

MADRID, May 12 (Reuters) - Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...